Urology (urological tumours)

Mainstreaming for R224 (inherited renal cancer) still has some way to go, but many patients tested by Clinical Genetics are eligible on the basis of readily identifiable factors such as age at diagnosis.

A key aim of this CoP is to support and promote a greater proportion of genomic tests initiated outside of Clinical Genetics Services, by treating teams across Trusts in the East region, thereby improving equity of access to testing and increasing the number of appropriate tests requested.

Where individuals are diagnosed with a predisposition to kidney cancer, regular surveillance imaging is usually indicated. However there is currently no coordination between centres to put this in place for affected patients. Therefore, another key aim of this pan-regional CoP would be to support this.

Please note: If you haven't already, you will need to register for an NHS Future account and request access to view the resources.

• Genetic conditions causing urological tumours (opens in a new tab)
• Assessing eligibility for genetic testing in urological tumours (opens in a new tab)
• Open Forum – Consent for Genetic Testing (opens in a new tab)
• Practical aspects of ordering germline genetic tests (opens in a new tab)
• Somatic genetic testing in Urological tumours (opens in a new tab)
• What happens after diagnosis of a Genetic condition predisposing to Urological tumours? - Focus on familial testing and surveillance (opens in a new tab)
• Prostate Cancer: Implementing the mainstream testing pathway into Urology Services across the EoE (opens in a new tab)
• Initiating genetic tests, the changing role of Clinical Genetics Departments (opens in a new tab)
• Prostate Cancer Screening in Relation to Heritable Conditions (opens in a new tab)
• A Rough Guide to the Mechanics of Next Generation Sequencing Tests (opens in a new tab)
• A Summary of the Key Points from the Year’s COP (opens in a new tab)